Brief: Diamyd Medical Updates On Strategic Review, Financial Position

Diamyd Medical AB

11/05/2026 07:35

May 11 (Reuters) - Diamyd Medical AB DMYDb.ST:

DIAMYD MEDICAL PROVIDES AN UPDATE ON STRATEGIC REVIEW AND FINANCIAL POSITION

IDENTIFIES SHORT LIST OF POTENTIAL COUNTERPARTIES IN STRATEGIC REVIEW

EVALUATING STRATEGIC ALTERNATIVES FOR UMEÅ BIOMANUFACTURING FACILITY

WILL NOT ALLOCATE FURTHER INTERNAL RESOURCES TO RETOGATEIN CLINICAL DEVELOPMENT

TO PREPARE RETOGATEIN DATA FOR POTENTIAL OUT-LICENSING OR PARTNERSHIP

REPORTS CASH POSITION OF SEK 366 MILLION

ESTIMATES CASH POSITION OF SEK 225 MILLION BY DECEMBER 31, 2026

Source text: ID:nWkr1QwG9

Further company coverage: [DMYDb.ST]

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com;))